Inventiva (IVA) Net Income towards Common Stockholders (2019 - 2021)

Inventiva (IVA) recorded quarterly Net Income towards Common Stockholders of -$10.2 million in Q2 2021, down 34.44% quarter-over-quarter from -$7.6 million in Q1 2021, and down 5.72% on a YoY basis from -$10.9 million in Q2 2020.

Inventiva (IVA) Net Income towards Common Stockholders (2019 - 2021) Analysis & Trends

Inventiva's Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at -$10.2 million for Q2 2021.

  • In Q2 2021, Net Income towards Common Stockholders fell 5.72% year-over-year to -$10.2 million; the TTM figure through Sep 2022 stood at -$10.2 million (changed N/A YoY), while the FY2025 annual figure was -$198.4 million, down 0.95% from the prior year.
  • Net Income towards Common Stockholders was -$10.2 million for Q2 2021 at Inventiva, down from -$7.6 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$7.5 million in Q1 2020 to a low of -$35.5 million in Q4 2020.
  • Historically, Net Income towards Common Stockholders has averaged -$17.3 million across 3 years, with a median of -$10.0 million in 2020.
  • The sharpest annual moves came in 2020 and 2021: Net Income towards Common Stockholders decreased 6.2% in 2020, then fell 1.78% in 2021.
  • A 3-year view of Net Income towards Common Stockholders shows it stood at -$33.4 million in 2019, then retreated by 6.2% to -$35.5 million in 2020, then jumped by 71.15% to -$10.2 million in 2021.
  • The last three Net Income towards Common Stockholders figures came in at -$10.2 million (Q2 2021), -$7.6 million (Q1 2021), and -$35.5 million (Q4 2020), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - -13.56 Mn
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn 2.50 Mn
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - -14.46 Mn
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - -3.63 Mn
7 Psyence Biomedical 227.32 Bn 227.31 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn 1.03 Bn
9 Abivax 91.71 Bn 91.71 Bn - -56.48 Mn
10 Inventiva 8.52 Mn -260.21 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2021 -10.23 Mn
Mar 31, 2021 -7.61 Mn
Dec 31, 2020 -35.45 Mn
Jun 30, 2020 -9.68 Mn
Mar 31, 2020 -7.48 Mn
Dec 31, 2019 -33.38 Mn